Opioid Addiction Treatment Options: Medications, Therapy, and Rehab

Opioid use disorder affects an estimated 2.7 million Americans age 12 and older, according to the 2022 National Survey on Drug Use and Health published by SAMHSA. Treatment is neither a single drug nor a single conversation — it spans FDA-approved medications, structured behavioral therapies, and levels of residential or outpatient care that range from a few hours a week to around-the-clock supervision. Knowing how those pieces fit together makes the difference between a treatment plan that holds and one that collapses under the first real pressure.

Definition and scope

Opioid use disorder (OUD) is classified in the DSM-5 as a chronic, relapsing brain disease characterized by compulsive opioid use despite harmful consequences, impaired control, and physiological dependence. The disorder spans a spectrum from mild (2–3 diagnostic criteria met) to severe (6 or more criteria), which is worth knowing because severity directly governs which treatment settings are clinically appropriate.

Treatment for OUD is not interchangeable with treatment for alcohol use disorder or stimulant disorders. Opioids bind to mu-opioid receptors in the brain's reward circuitry with a specificity that demands targeted pharmacological intervention — a fact the National Institute on Drug Abuse (NIDA) emphasizes in its treatment overview. Behavioral therapy alone, without medication, produces significantly worse outcomes for OUD than for most other substance use disorders.

The scope of opioid treatment in the United States includes federally regulated opioid treatment programs (OTPs), office-based opioid treatment (OBOT) settings, inpatient detox units, residential rehabilitation facilities, and intensive outpatient programs — each governed by different federal and state licensing requirements.

How it works

Treatment for OUD operates on two parallel tracks: pharmacological stabilization and behavioral restructuring. Neither track alone is sufficient for most patients with moderate-to-severe disorder.

Medications approved by the FDA for OUD:

1. Methadone — A full opioid agonist dispensed exclusively through federally certified OTPs. It suppresses withdrawal symptoms and cravings by occupying mu-opioid receptors without producing the euphoric peaks of illicit opioids. Dosing begins at 20–30 mg/day and is titrated to the individual, typically reaching 60–120 mg/day for optimal retention. Daily clinic attendance is required, at least initially.

2. Buprenorphine — A partial agonist with a "ceiling effect" that limits respiratory depression risk. Often combined with naloxone (sold as Suboxone) to deter injection misuse. Prescribers must hold a DEA registration; following the 2023 Consolidated Appropriations Act, the prior federal waiver requirement ("X-waiver") was eliminated, broadening prescriber access significantly.

3. Naltrexone (extended-release, injectable) — An opioid antagonist sold as Vivitrol. Unlike methadone or buprenorphine, it produces no opioid effect whatsoever and carries no abuse potential. The critical constraint: patients must complete full opioid detoxification — typically 7–10 days opioid-free — before the first injection, or precipitated withdrawal results. It suits patients with strong motivation and completed detox.

Methadone vs. buprenorphine is the comparison that shapes most OUD treatment decisions. Methadone offers stronger suppression for high-tolerance users but requires daily OTP visits. Buprenorphine permits take-home dosing from an office-based prescriber, which removes a significant logistical barrier — particularly for people managing work, childcare, or rural geography.

Behavioral therapy is layered on top of medication, not offered as an alternative. Cognitive Behavioral Therapy (CBT) targets the thought patterns that precede relapse. Contingency management provides structured positive reinforcement for negative drug screens. Twelve-step facilitation connects patients to community-based recovery networks. The NIDA Principles of Drug Addiction Treatment identifies behavioral therapies as essential components of any complete OUD treatment plan.

Common scenarios

Three treatment scenarios account for the majority of OUD cases presented to clinical programs:

• Acute withdrawal plus stabilization: A patient arriving in active withdrawal is typically managed in a medically supervised detox setting — hospital-based or residential — before any longer-term treatment begins. Methadone or buprenorphine induction often starts here.

• Stable maintenance treatment: A patient on a stable buprenorphine or methadone dose may remain in office-based or OTP care for months or years. SAMHSA guidelines explicitly state that indefinite medication-assisted treatment is clinically appropriate and should not be arbitrarily time-limited.

• Post-incarceration or post-overdose re-entry: Individuals leaving correctional facilities or recently surviving an overdose face sharply elevated relapse and overdose risk. Extended-release naltrexone has shown particular utility in this population in randomized trial data, because it sidesteps in-custody opioid diversion concerns. A 2011 randomized trial published in The Lancet found naltrexone injection significantly outperformed placebo in reducing relapse among Russian inmates following release.

Decision boundaries

Choosing between treatment options is not a matter of preference — it follows clinical logic shaped by tolerance level, social stability, and previous treatment history.

Extended-release naltrexone is contraindicated unless full detox is complete. Methadone is inappropriate for home-based initiation due to its narrow therapeutic index and QTc prolongation risk at higher doses. Buprenorphine carries precipitated withdrawal risk if administered before the patient reaches a COWS score (Clinical Opiate Withdrawal Scale) of 8 or higher, indicating sufficient withdrawal onset.

Setting matters as much as medication. The American Society of Addiction Medicine (ASAM) Patient Placement Criteria assigns patients to one of four care levels — from Level 0.5 (early intervention) to Level 4 (medically managed intensive inpatient) — based on six dimensions including withdrawal risk, medical complexity, and recovery environment. Understanding where a specific situation falls on that spectrum is the starting point for any treatment decision.

For a structured overview of how OUD treatment programs are organized and what distinguishes one level of care from another, the how it works section of this resource covers the full continuum. Answers to common questions about eligibility, cost, and access are compiled in the frequently asked questions section.